NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE192575 Query DataSets for GSE192575
Status Public on Jul 09, 2022
Title Acquired semi-squamalization during chemotherapy suggests a differentiation therapy for bladder cancer
Organisms Homo sapiens; Mus musculus
Experiment type Genome binding/occupancy profiling by high throughput sequencing
Summary Cisplatin-based chemotherapy is the most common treatment for unresectable bladder cancers and also increasingly used as neoadjuvant treatments before or after surgery and radiotherapy. Unfortunately, though many patients respond to the treatment, most of them develop resistance quickly with unclear mechanisms and few further treatment options. Here, we report that semi-squamazation is acquired during chemo treatment in both mice and human. Multi-omics analyses show that cathepsin H (CTSH), a direct target of p63, is associated with chemoresistance and semi-squamation. Treatment with the cathepsin inhibitor E64 specifically restrains chemoresistant but not chemosensitive cancer. Mechanistically, cathepsin inhibition induces fully squamous differentiation of bladder cancer cells, which requires TNF receptor 1alpha and is associated with pyroptosis. Our study suggests that semi-squamazation would be a diagnosistic marker for chemoresistance and differentiation therapy by targeting CTSH might be a potential treatment for chemoresistant bladder cancer.
 
Overall design Bulk RNAseq, ATAC-seq and sc-RNAseq in chemotherapy- sensitive and resistant mouse bladder cancer; sc-RNAseq in mouse chemo resistant tumors treated with vehicle or E64; Bulk RNAseq in chemotherapy-resistant mouse bladder cancer treated by E64 or vehicle; Bulk RNAseq and sc-RNAseq in chemotherapy-sensitive and resistant human bladder cancer.
 
Contributor(s) Chen X, Wang M, Tan P, Chen C
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Dec 24, 2021
Last update date Jul 12, 2022
Contact name Xaingyu Pan
E-mail(s) pangxueyu233@outlook.com
Organization name Sichuan University
Department State Key Laboratory of Biotherapy, West China Hospital, Sihcuan University.
Lab Chen & Liu Lab
Street address No.17 Renming road section3
City Chengdu, Cihna
State/province Sichuan
ZIP/Postal code 610041
Country China
 
Platforms (2)
GPL24247 Illumina NovaSeq 6000 (Mus musculus)
GPL24676 Illumina NovaSeq 6000 (Homo sapiens)
Samples (42)
GSM5751918 scRNA-seq, human, resistant
GSM5751919 scRNA-seq, human, sensitive
GSM5751920 scRNA-seq, mouse, resistant
Relations
BioProject PRJNA792084

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE192575_RAW.tar 489.3 Mb (http)(custom) TAR (of GAPPEDPEAK, TAR)
GSE192575_RNAseq1_mouse_Sen_vs_normal_result_all.csv.gz 2.0 Mb (ftp)(http) CSV
GSE192575_RNAseq2_mouse_Resis_vs_Sen_result_all.csv.gz 2.0 Mb (ftp)(http) CSV
GSE192575_RNAseq3_mouse_DDP_result_all.csv.gz 1.2 Mb (ftp)(http) CSV
GSE192575_RNAseq4_human_DDP_result_all.csv.gz 1.3 Mb (ftp)(http) CSV
GSE192575_RNAseq5_mouse_Resis_E64_VS_Vehicle_result_all.csv.gz 2.2 Mb (ftp)(http) CSV
SRA Run SelectorHelp
Raw data are available in SRA
Processed data provided as supplementary file
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap